LPA and peripheral arterial disease: Previous analyses within the EPIC-Norfolk dataset have confirmed that high Lp(a) levels are significantly associated with future risk of peripheral arterial disease, coronary artery disease and aortic stenosis [5], [15], a finding that underscores the need for compounds that specifically target Lp(a) (reviewed in Ref. [29]) as they could provide substantial cardiovascular benefits to patients with high Lp(a) if properly tested in cardiovascular outcomes trials.